By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A Nasdaq panel has granted Pressure BioSciences' request for continued listing on the exchange, the company said today.
The company still needs to comply with the Nasdaq's minimum $1 bid price requirement.
Separately, Nasdaq said that Rosetta must regain compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq by Aug. 8, 2011, for a minimum of 10 consecutive business days.
CombiMatrix had voluntarily applied for the transfer rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.
The firm also reported total shareholders' equity of approximately $4.9 million, which satisfies Amex's listing requirement of $4 million.
The company's stock began trading on the Nasdaq this morning. It had traded on the Pink Sheets since being delisted in 2008.
The World Health Organization has announced the members of its gene-editing committee, according to NPR.
DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.
The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.
In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.